Clinical Trial Detail

NCT ID NCT03996473
Title Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone Metastases
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements Yes
Sponsors Bayer
Indications

lung non-small cell carcinoma

Therapies

Pembrolizumab

Pembrolizumab + Radium Ra 223 dichloride

Age Groups: senior adult

Additional content available in CKB BOOST